The first method enabling quantification of tRNA abundance while simultaneously allowing for identification of tRNA modifications is now available, exclusively from Immagina.
IMMAGINA Biotechnology s.r.l. proudly holds the exclusive research use license for the groundbreaking nano-tRNAseq technology, originally developed by the Novoa Lab at the Centre for Genomic Regulation in Barcelona, Spain. This revolutionary technology was first introduced in the Nature Biotechnology publication “Quantitative analysis of tRNA abundance and modifications by nanopore RNA sequencing” on April 6, 2023. Marking a significant milestone in the fields of tRNA and translatomics, nano-tRNAseq enables the comprehensive sequencing of tRNA molecules in their full-length, native state, allowing for quantification of tRNA abundance and detection of tRNA modifications. This technology empowers researchers to easily pinpoint tRNA isoforms and post-translational modifications, offering a profound understanding of the intricate workings of these fundamental cellular components.
Immagina has taken this exclusively licensed innovative technology and made improvements to the published methods to provide a unique and comprehensive nano-tRNAseq service offering which includes multiplexing, comprehensive QC, and extensive bioinformatics reporting.
Contact us today to for early access to our nano-tRNAseq platform, with special introductory rates available through the end of the year.
- Expand Translatome Studies
- Quantify tRNA Abundance
- Identify tRNA Modifications
- Explore Ribo-Embedded tRNAseq
- Perform Codon-anticodon Analysis
- Maximize Drug Discovery Efforts
- Investigate tRNA Distribution in Tissues and Fluids